NASDAQ$ATAI
AtaiBeckley Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Atai Life Sciences reported financial results for Q4 2021 and provided business updates.
Atai Life Sciences ended 2021 with a strong cash position of $362 million. The company anticipates at least 14 drug development and enabling technology catalysts over the next two years. They are focused on rapid acting intervention, ongoing digital support and a biomarker-driven precision mental health.
- atai increased its holdings in COMPASS Pathways to 22.8% in Q4 2021.
- In December 2021, the FDA gave Investigational New Drug (IND) clearance for the development of PCN-101 for the treatment of TRD.
- atai announced positive biomarker data from the Phase 2a proof-of-mechanism study of RL-007 in CIAS patients in December of last year.
- atai ended the year with a strong cash position of $362 million which it anticipates will be sufficient to provide a cash runway of approximately two years.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
$230K
Forward guidance
The Company anticipates at least 14 drug development and enabling technology catalysts over the next two years.
Tailwinds
- Phase 2a proof-of-concept topline data readout with PCN-101 for TRD
- Results from the Phase 1 relative bioavailability study with PCN-101 designed to bridge between the current intravenous formulation to a subcutaneous formulation to support at-home use.
- Data from the Phase 1 element of a combined Phase 1/2 trial of DMX-1002 by the end of 2022
- Topline data from a Phase 1 trial with GRX-917 by mid of this year.
- Topline results for KUR-101 study later this year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+1.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | -6.0% | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro